Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Fate Therapeutics

Clinical trials sponsored by Fate Therapeutics, explained in plain language.

Fate Therapeutics FATE NASDAQ

A clinical-stage biopharmaceutical company developing cellular immunotherapies for cancer and immune disorders.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 3 Not yet recruiting 1 Not yet finished but already full! 1 Completed 1

Experimental cell therapy takes on tough blood cancers

Disease control Ongoing

This early-phase study tests a new treatment called FT819 for people with B-cell cancers (lymphoma, CLL, or B-ALL) that have not responded to standard therapies. The goal is to find a safe dose and see if the therapy can shrink tumors. About 54 participants will receive FT819 alo…

Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 11:03 UTC